{"id":144987,"date":"2025-02-14T09:27:31","date_gmt":"2025-02-14T03:57:31","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=144987"},"modified":"2025-02-14T09:27:31","modified_gmt":"2025-02-14T03:57:31","slug":"pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/","title":{"rendered":"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1932594061\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the pharmaceutical company specializing in developing and marketing generic formulations, biotechnology products, and APIs globally are in focus after management expects to reach an EBITA Margin of 22.5 percent to 23.5 percent for FY25.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1712223301\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price action<\/strong><\/h2><p>With a market capitalization of Rs. 95,632.77 Crores on Friday, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/LUPIN\" target=\"_blank\" rel=\"noreferrer noopener\">Lupin Limited<\/a><\/strong> rose by 1.61 percent after making a high of Rs. 2088.65 compared to its previous closing price of Rs. 2055.65.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Lupin at Glance<\/strong><\/h2><p>The company specializes in generics, biotechnology, and APIs it focuses on providing high-quality, affordable medicines across various therapeutic areas, including cardiovascular, oncology, and respiratory.&nbsp;<\/p><p>Lupin is a global pharmaceutical leader with a strong presence in over 100 countries. It ranks 12th globally in generics by sales and is the largest generic company in the US, Australia, South Africa, and more.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2221407783\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>With annual sales of $2.4 billion and 23,000+ employees, Lupin focuses on sustainable growth and innovation, operating 15 manufacturing sites and 7 R&amp;D sites globally, and has planned to set up 58MW Renewable energy capacity by FY25.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Guidance of Lupin Ltd<\/strong><\/h2><p>According to the company\u2019s recent conference call update, they target EBITDA margins of 22.5 percent to 23.5 percent for FY25, with an effective tax rate (ETR) of 20 percent to 21 percent for FY25 and their specialty product performance expected to be significant into the fiscal year 2027.<\/p><p>The company reported a 51 basis point expansion in EBITDA margins on a quarter-on-quarter basis and has strong product pipelines including 20 respiratory and 40 injectable products under development.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financial Performace (Q3FY25)<\/strong><\/h2><p>The company\u2019s Revenue from operations grew by 10.9 percent YoY from Rs. 5,197.4 crores in Q3FY24 to Rs. 5,767.7 crores in Q3FY25 and it grew by<strong> <\/strong>1.6<strong> <\/strong>percent QoQ from Rs. 5,672.7 crores in Q2FY25 to Rs. 5,767.7 crores in Q3FY25.<\/p><p>Its Net Profit rose 38 percent YoY from Rs. 618.7 crores in Q3FY24 to Rs. 858.8 crores in Q3FY25 and it fell by 0.06 percent QoQ from Rs. 859.4 crores in Q2FY25 to Rs. 858.8 crores in Q3FY25.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Key Business&nbsp; Developments (Q3FY25)<\/strong><\/h2><p>The company has acquired Eli Lilly\u2019s Huminsulin to enhance India&#8217;s Diabetes Portfolio and they have partnered to commercialize NaMuscla in Argentina &amp; Colombia and have filed&nbsp; Ranibizumab for European Union (EU) markets.<\/p><div class=\"trade-content-10\" id=\"trade-2524818699\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading\"><strong>Segment Revenue&nbsp;<\/strong><\/h2><p>Lupin Limited segment revenue is distributed across two services as follows: pharmaceuticals segment revenue grew from Rs. 5,742 crores in&nbsp; Q2FY25 to Rs. 5,647.2 crores in Q3FY25 and the Others segment grew from&nbsp; Rs. 26.3&nbsp; crores in Q2FY25 to Rs. 26.2 crores in Q3FY25.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Sridhar J&nbsp;<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-2515426484\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the pharmaceutical company specializing in developing and marketing generic formulations, biotechnology products, and APIs globally are in focus after management expects to reach an EBITA Margin of 22.5 percent to 23.5 percent for FY25. Price action With a market capitalization of Rs. 95,632.77 Crores on Friday, the shares of Lupin Limited rose [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[2383,775,9151,770,19834,6616,948,936,2597],"class_list":["post-144987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-lupin","tag-lupin-india","tag-lupin-latest-news","tag-lupin-share","tag-lupin-share-price","tag-pharma-stock","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on\" \/>\n<meta property=\"og:description\" content=\"The shares of the pharmaceutical company specializing in developing and marketing generic formulations, biotechnology products, and APIs globally are in focus after management expects to reach an EBITA Margin of 22.5 percent to 23.5 percent for FY25. Price action With a market capitalization of Rs. 95,632.77 Crores on Friday, the shares of Lupin Limited rose [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-14T03:57:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/\",\"name\":\"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2025-02-14T03:57:31+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on","og_description":"The shares of the pharmaceutical company specializing in developing and marketing generic formulations, biotechnology products, and APIs globally are in focus after management expects to reach an EBITA Margin of 22.5 percent to 23.5 percent for FY25. Price action With a market capitalization of Rs. 95,632.77 Crores on Friday, the shares of Lupin Limited rose [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-02-14T03:57:31+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png","type":"image\/png"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/","name":"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2025-02-14T03:57:31+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-high-ebitda-margin-of-23-for-fy25-to-keep-a-watch-on\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock with high EBITDA margin of 23% for FY25 to keep a watch on"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/144987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=144987"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/144987\/revisions"}],"predecessor-version":[{"id":144988,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/144987\/revisions\/144988"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=144987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=144987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=144987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}